Great Point Partners

165 Mason Street
Greenwich, CT 6830

Website: gppfunds.com

Firm Size

• Assets Under Management (AUM):$1.9 Billion
• Number of Funds:19
• Employees:28
• Firm Type:Private Equity
• Focus Areas: Software & Technology
  Services
  Healthcare
  

Description

Great Point Partners, LLC is an investment management firm based in Greenwich, CT. Founded in 2003, the company specializes in healthcare investments, particularly in the biopharmaceutical and medical device industries. Great Point Partners manages several funds and focuses on making both minority and control investments in growth-oriented healthcare companies. The firm's investment strategy revolves around identifying promising healthcare companies that have disruptive technologies or innovative products. They provide not only capital but also strategic guidance and operational expertise to help these companies achieve their full potential. Great Point Partners aims to create long-term value for their investors by actively participating in the growth and development of their portfolio companies. In addition to their investment activities, Great Point Partners also offers advisory services to healthcare companies, assisting them with mergers and acquisitions, strategic planning, and operational improvements. The firm prides itself on its deep sector knowledge and extensive network, which allows them to identify and capitalize on investment opportunities within the healthcare industry. Overall, Great Point Partners, LLC is a well-established investment management firm that focuses on healthcare investments. Through their capital, resources, and expertise, they support the growth and success of their portfolio companies, while also providing advisory services to healthcare firms.

Latest News

Powered by

Dec 21, 2023: Ziegler Advises Ludi On Growth Recapitalization With Great Point Partners


Dec 07, 2023: Spyre Therapeutics Announces $180 Million Private Placement
Spyre Therapeutics, Inc. ("Spyre") (NASDAQ: SYRE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $180 million to the Company, before deducting placement agent fees and offering expenses. The PIPE financing included participation from both new and existing investors, including Access Biotechnology, Venrock Healthcare Capital Partners, Perceptive Advisors, RTW Investments, LP, Braidwell LP, Fairmount, Cormorant Asset Management, Polar Capital, Boxer Capital, Deep Track Capital, Great Point Partners LLC, Affinity Asset Advisors, Commodore Capital, Woodline Partners LP, a leading biotechnology investor associated with one of the largest alternative asset managers, and a large investment management firm.